Immutep Ltd (ASX: IMM) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Immutep Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$38.33 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
1.47 billion
Earnings per share
-0.054
Dividend per share
N/A
Year To Date Return
-93.25%
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Immutep Ltd (ASX: IMM)
Latest News
Healthcare Shares
Why this ASX biotech stock just rocketed 89% today
Healthcare Shares
Down 87% since Thursday, why is this ASX 300 healthcare stock sliding again today?
Healthcare Shares
How does Bell Potter rate these ASX healthcare stocks?
Share Fallers
Why CAR Group, Immutep, Northern Star, and Syrah Resources shares are sinking today
Healthcare Shares
Game over? ASX biotech stock crashes 90% on big bad news
Healthcare Shares
Why the Immutep share price is halted today
Healthcare Shares
Up 43% since December, ASX 300 healthcare share announces milestone achievement
Healthcare Shares
This ASX biotech just smashed its quarterly update. So why are its shares falling?
Healthcare Shares
Clinical trial of potential diabetes and arthritis treatment delivers positive results
Small Cap Shares
Broker says this small cap ASX stock can rise ~90% following 'impressive deal'
Share Gainers
Why Brightstar Resources, Immutep, Pilbara Minerals, and Race Oncology shares are roaring higher
Healthcare Shares
Guess which ASX 300 healthcare share is rocketing 28% on global expansion news
Frequently Asked Questions
-
No, Immutep does not pay dividends at this time.
-
Immutep Ltd listed on the ASX on 23 June 1988.
IMM ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Immutep Ltd
Immutep Ltd (ASX: IMM) is a biotechnology company developing immunotherapy products for cancer and autoimmune diseases. The company describes itself as a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Immutep's LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune diseases. Immutep currently has three clinical-stage candidates and two earlier-stage candidates.
IMM Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 09 Oct 2026 | $0.03 | $0.00 | 0.00% | 12,156,580 | $0.03 | $0.03 | $0.03 |
| 08 Oct 2026 | $0.03 | $0.00 | 0.00% | 6,675,855 | $0.03 | $0.03 | $0.03 |
| 07 Oct 2026 | $0.03 | $0.00 | 0.00% | 12,583,749 | $0.03 | $0.03 | $0.03 |
| 06 Oct 2026 | $0.03 | $0.00 | 0.00% | 8,332,446 | $0.03 | $0.03 | $0.03 |
| 05 Oct 2026 | $0.03 | $0.00 | 0.00% | 7,067,452 | $0.03 | $0.03 | $0.03 |
| 02 Oct 2026 | $0.03 | $0.00 | 0.00% | 24,951,559 | $0.03 | $0.03 | $0.03 |
| 01 Oct 2026 | $0.03 | $0.00 | 0.00% | 4,232,785 | $0.03 | $0.03 | $0.03 |
| 30 Sep 2026 | $0.03 | $0.00 | 0.00% | 4,497,329 | $0.03 | $0.04 | $0.03 |
| 29 Sep 2026 | $0.03 | $0.00 | 0.00% | 7,182,179 | $0.04 | $0.04 | $0.03 |
| 28 Sep 2026 | $0.03 | $0.00 | 0.00% | 17,593,081 | $0.04 | $0.04 | $0.03 |
| 25 Sep 2026 | $0.04 | $0.00 | 0.00% | 15,925,520 | $0.04 | $0.04 | $0.04 |
| 24 Sep 2026 | $0.04 | $0.00 | 0.00% | 17,738,514 | $0.04 | $0.04 | $0.04 |
| 23 Sep 2026 | $0.04 | $0.00 | 0.00% | 16,350,285 | $0.04 | $0.04 | $0.04 |
| 22 Sep 2026 | $0.04 | $0.00 | 0.00% | 6,454,957 | $0.04 | $0.04 | $0.04 |
| 21 Sep 2026 | $0.04 | $0.00 | 0.00% | 17,812,396 | $0.04 | $0.04 | $0.04 |
| 18 Sep 2026 | $0.04 | $-0.01 | -22.22% | 88,325,209 | $0.05 | $0.05 | $0.04 |
| 17 Sep 2026 | $0.05 | $0.00 | 0.00% | 9,021,036 | $0.05 | $0.05 | $0.04 |
| 16 Sep 2026 | $0.05 | $0.00 | 0.00% | 8,697,659 | $0.05 | $0.05 | $0.04 |
| 15 Sep 2026 | $0.05 | $0.00 | 0.00% | 18,435,318 | $0.05 | $0.05 | $0.04 |
| 14 Sep 2026 | $0.05 | $-0.01 | -17.86% | 21,113,896 | $0.05 | $0.05 | $0.05 |
| 11 Sep 2026 | $0.06 | $0.01 | 22.73% | 45,816,068 | $0.05 | $0.06 | $0.04 |
| 10 Sep 2026 | $0.04 | $0.00 | 0.00% | 12,826,028 | $0.05 | $0.05 | $0.04 |
| 09 Sep 2026 | $0.05 | $0.00 | 0.00% | 8,083,492 | $0.05 | $0.05 | $0.05 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 02 Oct 2026 | Pete Meyers | Expiry | 2,058,631 | $65,876 |
As advised by the company. 2,058,631 Rights lapsed
|
| 01 Oct 2026 | Pete Meyers | Buy | 388,889 | $12,833 |
Conversion of securities.
|
| 01 Oct 2026 | Pete Meyers | Exercise | 388,889 | $12,833 |
Conversion of securities. 2,058,631 Performance Rights
|
| 04 Dec 2025 | Russell Howard | Issued | 300,000 | $76,500 |
Conversion of securities.
|
| 04 Dec 2025 | Russell Howard | Exercise | 300,000 | $76,500 |
Conversion of securities. 13,73,646 Rights
|
| 02 Dec 2025 | Lis (Elisabeth) Boyce | Exercise | 166,667 | $46,666 |
Conversion of securities. 1,66,667 Rights
|
| 02 Dec 2025 | Lis (Elisabeth) Boyce | Issued | 707,232 | $198,024 |
Director remuneration. 8,73,899 Rights
|
| 02 Dec 2025 | Lis (Elisabeth) Boyce | Issued | 166,667 | $46,666 |
Conversion of securities.
|
| 02 Dec 2025 | Russell Howard | Issued | 1,573,646 | $440,620 |
Issue of securities. 16,73,646 Rights
|
| 01 Dec 2025 | Pete Meyers | Issued | 2,058,631 | $607,296 |
Director remuneration. 24,47,520 Rights
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Dr Russell J Howard | Non-Executive ChairmanNon-Executive Director | May 2013 |
Dr Howard is an executive manager, and entrepreneur. He is an inventor of 9 patents and has over 140 scientific publications. He held positions at several research laboratories, including the National Institutes of Health in the USA where he gained tenure. In industry, Dr Howard worked at Schering-Ploughs DNAX Research Institute in Palo Alto, CA, was the President and Scientific Director of Affymax, Inc. and co-founder and CEO of Maxygen, Inc. After its spin-out from GlaxoWellcome as Maxygens CEO. After leaving Maxygen in 2008, he started the Cleantech company Oakbio Inc (dba NovoNutrients) and remains involved in several innovative companies in the USA and Australia. He is currently Non-Executive Chairman of NeuClone Pty Ltd.He is a member of risk committee.
|
| Mr Marc Voigt | Chief Financial OfficerChief Executive OfficerExecutive Director | May 2012 |
Mr Voigt has more than 25 years of experience in the financial and biotech industry. He worked for a number of years as an investment manager for a midsize venture capital fund based in Berlin, in healthcare. He has operational experience while serving in different management roles with Revotar Biopharmaceuticals, Caprotec Bioanalytics and Medical Enzymes AG respectively, where he handled several licensing transactions and financing rounds. Since 2001, Marc has been a judge and coach in BPW. He is also member of the investment committee of an Australian venture capital fund.
|
| Professor Frederic Triebel | Executive Director | Sep 2022 |
Prof Triebel, was a Professor in Immunology at Paris University. While working at Institut Gustave Roussy (IGR), a cancer centre in Paris, he discovered the LAG-3 gene in 1990 and continued working on this research program since then, identifying the functions and medical usefulness of this molecule. He headed a research group at IGR while also being involved in the biological follow up of cancer patients treated in Phase I/II immunotherapy trials. He was Director of an INSERM Unit from 1991 to 1996. First trained as a clinical haematologist.
|
| Ms Lis (Elisabeth) Boyce | Non-Executive Director | Apr 2023 |
Ms Boyce has 35 years experience including capital raising, strategic collaborations, corporate governance and mergers & acquisitions. She is a partner in Piper Aldermans corporate team, and co-chairs the firms Life Sciences & Healthcare focus group. She is a member of risk committee.
|
| Ms Deanne Miller | Chief Operating OfficerCompany SecretaryGeneral Counsel |
-
|
|
| Deanne Miller | Chief Operating OfficerCompany SecretaryGeneral Counsel |
-
|
|
| Christian Mueller | Other Corporate Officer |
-
|
|
| Stephan Winckels | Other Corporate Officer |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| HSBC Custody Nominees (Australia) Limitedi | 447,266,310 | 30.35% |
| Citicorp Nominees Pty Limited | 167,412,914 | 11.36% |
| J P Morgan Nominees Australia Pty Limited | 72,601,654 | 4.93% |
| HSBC Custody Nominees (Australia) Limitedii | 43,750,066 | 2.97% |
| BNP Paribas Nominees Pty Ltdi | 17,886,315 | 1.21% |
| BNP Paribas Nominees Pty Ltdii | 17,738,958 | 1.20% |
| BNP Paribas Noms Pty Ltd | 17,212,822 | 1.17% |
| Marc Voigt | 14,876,945 | 1.01% |
| BNP Paribas Nominees Pty Ltd <Agency Lending A/C> | 12,214,139 | 0.83% |
| Mr Matthew Caudle | 11,440,910 | 0.78% |
| Frederic Triebel | 11,353,764 | 0.77% |
| AG Investment Services Pty Ltd | 10,186,037 | 0.69% |
| UBS Nominees Pty Ltd | 9,404,321 | 0.64% |
| Tina Danali Pty Ltd <The Henderson Family A/C> | 9,000,000 | 0.61% |
| Macenrock Pty Ltd <Macenrock S/F A/C> | 7,583,508 | 0.51% |
| Angus Family Nominees Pty Ltd <Angus Family A/C> | 7,147,472 | 0.48% |
| BNP Paribas Nominees Pty Ltdiii | 6,667,046 | 0.45% |
| Mr Vinh Ho The Vo | 6,000,000 | 0.41% |
| Mr Wei Li | 5,700,000 | 0.39% |
| Mr Jordan Guocheng Li & Miss Weihong Zhao <Li Family A/C> | 5,500,000 | 0.37% |
| North Shore Advisory Group Pty Ltd | 5,500,000 | 0.37% |
